Published Online
on February 24, 2003

A more recent version of this article appeared on March 1, 2003

This Article Full Text (PDF) All Versions of this Article: 41/3/398    most recent 01.HYP.0000057010.27011.2Cv1 Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sciarrone, M. T. Articles by Cusi, D. Search for Related Content PubMed PubMed Citation Articles by Sciarrone, M. T. Articles by Cusi, D. Related Collections Clinical genetics ACE/Angiotension receptors Genetics of cardiovascular disease

Submitted on March 12, 2002
Revised on April 9, 2002

ACE and -Adducin Polymorphism as Markers of Individual Response to Diuretic Therapy

Maria Teresa Sciarrone^*; Paola Stella; Cristina Barlassina; Paolo Manunta; Chiara Lanzani; Giuseppe Bianchi; and Daniele Cusi

From the Department of Nephrology and Graduate School of Nephrology Universita' Vita e Salute, Milan; and Division of Nephrology, Dialysis, and Hypertension, S. Raffaele Hospital, Milan, Italy.

^* To whom correspondence should be addressed. E-mail: sciarronealibrandi.mariateresa{at}hsr.it.

Abstract--Renin-angiotensin system reactivity and the constitutive capacity of the renal tubule to reabsorb sodium play a role in the individual response to diuretic therapy; therefore we evaluated the blood pressure (BP) response to hydrochlorothiazide in 87 never-treated individuals with mild essential hypertension, according to ACE gene I/D and -adducin Gly460Trp polymorphism. These genotypes where chosen because previous data showed their interaction in determining the BP response to salt probably was the result of their involvement in the activation of the renin-angiotensin system (ACE) and in the constitutive capacity of the kidney to reabsorb sodium (-adducin) (treatment for 2 months). BP was measured after 3 run-in visits and after the first and second months of treatment by means of a standardized procedure. Data were analyzed by ANOVA, t test, and multivariate ANOVA for repeated measures (covarying for gender, age, and body mass index). Although basal mean BP (MBP) was similar in the different ACE and -adducin genotypes, patients carrying at least one I allele of ACE and one 460Trp allele of -adducin had the largest MBP decrease with treatment (12.7±1.9 mm Hg), the effect of the combination of genotypes being additive but not epistatic. These patients had an odds ratio of 15.75 of being a responder to hydrochlorothiazide compared with patients with Gly460Gly+DD, with the least MBP decrease (3.4±1.7 mm Hg). -Adducin and ACE I/D polymorphism may be useful to predict the interindividual degree of response to hydrochlorothiazide; the analysis of the combination of the 2 genotypes increases the accuracy of the prediction of response to the drug.

Key words: genetics • renin-angiotensin system • sodium • polymorphism • hypertension, essential

This article has been cited by other articles:

				G. Capasso, M. Rizzo, M. L. Garavaglia, F. Trepiccione, M. Zacchia, A. Mugione, P. Ferrari, M. Paulmichl, F. Lang, J. Loffing, et al. Upregulation of apical sodium-chloride cotransporter and basolateral chloride channels is responsible for the maintenance of salt-sensitive hypertension Am J Physiol Renal Physiol, August 1, 2008; 295(2): F556 - F567. [Abstract] [Full Text] [PDF]

				P. Manunta, G. Lavery, C. Lanzani, P. S. Braund, M. Simonini, C. Bodycote, L. Zagato, S. Delli Carpini, C. Tantardini, E. Brioni, et al. Physiological Interaction Between {alpha}-Adducin and WNK1-NEDD4L Pathways on Sodium-Related Blood Pressure Regulation Hypertension, August 1, 2008; 52(2): 366 - 372. [Abstract] [Full Text] [PDF]

				K. M. Momary Cardiovascular Pharmacogenomics Journal of Pharmacy Practice, June 1, 2007; 20(3): 265 - 276. [Abstract] [PDF]

				Y. Li, L. Zagato, T. Kuznetsova, G. Tripodi, G. Zerbini, T. Richart, L. Thijs, P. Manunta, J.-G. Wang, G. Bianchi, et al. Angiotensin-Converting Enzyme I/D and {alpha}-Adducin Gly460Trp Polymorphisms: From Angiotensin-Converting Enzyme Activity to Cardiovascular Outcome Hypertension, June 1, 2007; 49(6): 1291 - 1297. [Abstract] [Full Text] [PDF]

				P. Manunta and G. Bianchi Pharmacogenomics and Pharmacogenetics of Hypertension: Update and Perspectives--The Adducin Paradigm J. Am. Soc. Nephrol., April 1, 2006; 17(4_suppl_2): S30 - S35. [Abstract] [Full Text] [PDF]

				S. Padmanabhan, C. Wallace, P. B. Munroe, R. Dobson, M. Brown, N. Samani, D. Clayton, M. Farrall, J. Webster, M. Lathrop, et al. Chromosome 2p Shows Significant Linkage to Antihypertensive Response in the British Genetics of Hypertension Study Hypertension, March 1, 2006; 47(3): 603 - 608. [Abstract] [Full Text] [PDF]

				M. E. Ernst, B. L. Carter, C. J. Goerdt, J. J.G. Steffensmeier, B. B. Phillips, M. B. Zimmerman, and G. R. Bergus Comparative Antihypertensive Effects of Hydrochlorothiazide and Chlorthalidone on Ambulatory and Office Blood Pressure Hypertension, March 1, 2006; 47(3): 352 - 358. [Abstract] [Full Text] [PDF]

				H. Schelleman, O. H Klungel, C. M van Duijn, J. C. Witteman, A. Hofman, A. de Boer, and B. H. Stricker Drug-Gene Interaction Between the Insertion/Deletion Polymorphism of the Angiotensin-Converting Enzyme Gene and Antihypertensive Therapy Ann. Pharmacother., February 1, 2006; 40(2): 212 - 218. [Abstract] [Full Text] [PDF]

				G. Bianchi Genetic variations of tubular sodium reabsorption leading to "primary" hypertension: from gene polymorphism to clinical symptoms Am J Physiol Regulatory Integrative Comp Physiol, December 1, 2005; 289(6): R1536 - R1549. [Abstract] [Full Text] [PDF]

				Y. Li, L. Thijs, T. Kuznetsova, L. Zagato, H. Struijker-Boudier, G. Bianchi, and J. A. Staessen Cardiovascular Risk in Relation to {alpha}-Adducin Gly460Trp Polymorphism and Systolic Pressure: A Prospective Population Study Hypertension, September 1, 2005; 46(3): 527 - 532. [Abstract] [Full Text] [PDF]

				D. K. Arnett, B. R. Davis, C. E. Ford, E. Boerwinkle, C. Leiendecker-Foster, M. B. Miller, H. Black, and J. H. Eckfeldt Pharmacogenetic Association of the Angiotensin-Converting Enzyme Insertion/Deletion Polymorphism on Blood Pressure and Cardiovascular Risk in Relation to Antihypertensive Treatment: The Genetics of Hypertension-Associated Treatment (GenHAT) Study Circulation, June 28, 2005; 111(25): 3374 - 3383. [Abstract] [Full Text] [PDF]

				J. A. Johnson and L. H. Cavallari Cardiovascular pharmacogenomics Exp Physiol, May 1, 2005; 90(3): 283 - 289. [Abstract] [Full Text] [PDF]

				G. Bianchi, P. Ferrari, and J. A. Staessen Adducin Polymorphism: Detection and Impact on Hypertension and Related Disorders Hypertension, March 1, 2005; 45(3): 331 - 340. [Abstract] [Full Text] [PDF]

				M. H. Weinberger More on the Sodium Saga Hypertension, November 1, 2004; 44(5): 609 - 611. [Full Text] [PDF]

				E. Beeks, M. M. van der Klauw, A. A. Kroon, W. Spiering, M. J.M.J. Fuss-Lejeune, and P. W. de Leeuw {alpha}-Adducin Gly460Trp Polymorphism and Renal Hemodynamics in Essential Hypertension Hypertension, October 1, 2004; 44(4): 419 - 423. [Abstract] [Full Text] [PDF]

				F. C. Luft Geneticism of Essential Hypertension Hypertension, June 1, 2004; 43(6): 1155 - 1159. [Full Text] [PDF]

				P. Manunta and G. Bianchi Low-Salt Diet and Diuretic Effect on Blood Pressure and Organ Damage J. Am. Soc. Nephrol., January 1, 2004; 15(90010): S43 - 46. [Abstract] [Full Text]

				I. Narita, S. Goto, N. Saito, J. Song, J. Ajiro, F. Sato, D. Saga, D. Kondo, K. Akazawa, M. Sakatsume, et al. Interaction Between ACE and ADD1 Gene Polymorphisms in the Progression of IgA Nephropathy in Japanese Patients Hypertension, September 1, 2003; 42(3): 304 - 309. [Abstract] [Full Text] [PDF]